Cohance Lifesciences cash flow

Latest FY26

Cash from operations: ₹368cr+27.8% on FY25
Capital spending: ₹220cr+41.2% on FY25
Free cash flow: ₹148cr+12.1% on FY25
Cash from financing: −₹165cr₹3.3 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	187	77.5	51.8	46.5
	—	34.6	11.5	7.5	5.4
	—	−2.7	−1.3	−1.9	0.0
	—	17.1	−3.2	0.0	0.0
	—	−3.8	14.9	0.0	0.0
	—	−25.0	0.6	0.7	0.0
	—	0.0	0.0	2.2	0.0
	—	0.0	0.0	−44.8	0.0
	—	0.7	−40.2	0.0	0.0
	—	−94.6	74.1	81.6	−29.4
	—	103	−148	−22.8	0.0
	—	0.0	0.0	0.0	124
	—	0.0	0.0	35.5	−20.4
	—	0.0	0.0	−23.8	−15.5
	—	12.8	41.7	−28.2	−40.7
	—	0.0	0.0	−1.7	0.0
	—	0.0	0.0	0.0	−8.8
	—	0.0	0.0	4.3	−2.9
	—	0.0	0.0	0.4	−0.4
	—	0.0	0.0	2.2	−0.6
Cash from operating activities
	101	207	344	406	560
	—	229	27.7	62.8	57.5
	—	436	372	468	617
	—	0.0	0.0	0.0	−5.8
	—	0.0	0.0	0.0	−14.7
	—	67.8	83.4	110	146
	—	368	288	358	451
Cash from investing activities
	—	220	156	51.8	286
	—	20.5	0.0	0.0	0.1
	—	1.5	348	311	0.0
	—	0.0	971	1.1	0.0
	—	0.0	728	0.0	0.0
	—	3.0	0.2	1.9	5.8
	—	−56.7	4.8	−2.4	85.0
	—	−255	−255	−362	−195
Cash from financing activities
	—	32.4	0.0	0.0	0.0
	—	0.0	24.6	0.0	0.0
	—	93.7	1.9	31.6	26.4
	—	37.6	15.8	−25.2	0.4
	—	16.3	3.6	7.5	5.4
	—	0.0	0.0	0.0	204
	—	−50.0	0.0	0.0	0.0
	—	−165	3.3	−13.8	−236
	—	−51.4	36.2	−17.6	20.2
	—	3.9	2.0	0.0	0.0
	—	−47.5	38.2	−17.6	20.2
	—	—	85.4	47.2	64.8
Reference items
	316	427	375	406	567
	14.8%	18.8%	31.3%	38.6%	42.3%
	148	148	132	307	165
	—	224	168	269	—
	₹3.88	₹3.88	₹3.46	₹8.02	₹4.32
	124.07×	—	—	—	—
	—	2.45×	1.09×	1.19×	1.10×
	—	67.8	83.4	110	146
	—	16.3	3.6	7.5	5.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

COHANCE₹481.35

Cohance Lifesciences Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB SYNGENE ASTERDM LALPATHLAB NATCOPHARM WOCKPHARMA NEULANDLAB NHMcap ₹18,416 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	46.5	51.8	77.5	187.3	—
+ Finance Costs	5.4	7.5	11.5	34.6	—
+ Interest Income	0.0	-1.9	-1.3	-2.7	—
+ Fair Value (Gains) / Losses	0.0	0.0	-3.2	17.1	—
+ Share-based Payments	0.0	0.0	14.9	-3.8	—
+ Unrealised FX (Gain) / Loss	0.0	0.7	0.6	-25.0	—
+ Other Non-cash Items	0.0	2.2	0.0	0.0	—
+ Other — Cash Effects are Investing / Financing	0.0	-44.8	0.0	0.0	—
+ Other Reconciling Items	0.0	0.0	-40.2	0.7	—
Changes in Working Capital
+ Inventories	-29.4	81.6	74.1	-94.6	—
+ Trade Receivables — Current	0.0	-22.8	-148.0	102.5	—
+ Trade Receivables — Non-current	124.5	0.0	0.0	0.0	—
+ Other Current Assets	-20.4	35.5	0.0	0.0	—
+ Other Non-current Assets	-15.5	-23.8	0.0	0.0	—
+ Trade Payables — Current	-40.7	-28.2	41.7	12.8	—
+ Other Financial Liabilities — Current	0.0	-1.7	0.0	0.0	—
+ Other Financial Liabilities — Non-current	-8.8	0.0	0.0	0.0	—
+ Other Current Liabilities	-2.9	4.3	0.0	0.0	—
+ Provisions — Current	-0.4	0.4	0.0	0.0	—
+ Provisions — Non-current	-0.6	2.2	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	559.7	405.7	343.9	207.0	101.4
+ Total Adjustments (incl. Working Capital)	57.5	62.8	27.7	229.1	—
Cash from Operations (pre-tax)	617.3	468.4	371.6	436.1	—
+ Interest Received — Operating	-5.8	0.0	0.0	0.0	—
+ Other Inflows / (Outflows) — Operating	-14.7	0.0	0.0	0.0	—
+ Income Taxes Paid	145.8	110.0	83.4	67.8	—
Cash from Operating Activities	450.9	358.5	288.2	368.3	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	285.8	51.8	155.7	219.9	—
+ Disp of Fixed Assets	0.1	0.0	0.0	20.5	—
+ Acq of Other Long-term Assets	0.0	311.2	348.1	1.5	—
+ Disp of Other Long-term Assets	0.0	1.1	971.5	0.0	—
+ Acq of Subsidiaries / Businesses (net)	0.0	0.0	728.0	0.0	—
+ Interest Received — Investing	5.8	1.9	0.2	3.0	—
+ Other Inflows / (Outflows) — Investing	85.0	-2.4	4.8	-56.7	—
Cash from Investing Activities	-194.8	-362.3	-255.3	-254.6	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	0.0	0.0	0.0	32.4	—
+ Proceeds from Borrowings	0.0	0.0	24.6	0.0	—
+ Repayment of Borrowings	26.4	31.6	1.9	93.7	—
+ Payment of Lease Liabilities	0.4	-25.2	15.8	37.6	—
+ Interest Paid	5.4	7.5	3.6	16.3	—
+ Dividends Paid	203.7	0.0	0.0	0.0	—
+ Other Inflows / (Outflows) — Financing	0.0	0.0	0.0	-50.0	—
Cash from Financing Activities	-235.8	-13.8	3.3	-165.2	—
Net Changes in Cash (pre-FX)	20.2	-17.6	36.2	-51.4	—
+ Effect of FX Rate Changes on Cash	0.0	0.0	2.0	3.9	—
Net Changes in Cash	20.2	-17.6	38.2	-47.5	—
Closing Cash	64.8	47.2	85.4	—	—
Reference Items
EBITDA	566.5	405.8	375.2	427.0	316.1
EBITDA Margin %	42.27	38.60	31.33	18.82	14.76
Free Cash Flow (CFO − Capex)	165.1	306.7	132.5	148.4	148.4
Free Cash Flow to Equity	—	268.7	168.4	223.7	—
Free Cash Flow per Basic Share	4.32	8.02	3.46	3.88	3.88
Price to Free Cash Flow	—	—	—	—	124.07
Cash Flow to Net Income	1.10	1.19	1.09	2.45	—
Cash Paid for Taxes	145.8	110.0	83.4	67.8	—
Cash Paid for Interest	5.4	7.5	3.6	16.3	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.